Kloess Stephan, Kretschmer Anna, Stahl Lilly, Fricke Stephan, Koehl Ulrike
Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Institute for Cellular Therapeutics, ATMP-GMPDU, Hannover Medical School, Hannover, Germany.
Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5.
Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an "off the shelf product" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.
自2017年Kymriah®和Yescarta®获批且取得显著成功以来，研究嵌合抗原受体修饰的自体T细胞安全性和有效性的临床试验数量一直在不断增加。目前，clinicaltrial.gov上列出了200多项临床试验。与CAR-T细胞不同，自然杀伤（NK）细胞可作为“现成产品”从异体供体获取，为癌症重定向提供了替代候选方案。本综述总结了使用原代人NK细胞和NK-92细胞系的CAR工程化NK细胞的临床前结果，并分别概述了针对血液系统恶性肿瘤和实体瘤的首批CAR-NK细胞临床研究。
